Genmab acquires biotechnology company ProfoundBio in $1.8bn deal
Genmab has concluded the acquisition of ProfoundBio, a clinical-stage biotechnology company, in an all-cash transaction valued at $1.8bn.
Genmab has concluded the acquisition of ProfoundBio, a clinical-stage biotechnology company, in an all-cash transaction valued at $1.8bn.
What's Your Reaction?
